5-Aryl-4-(5-substituted-2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 4, 2009, Pages 1089-1092

  Cikotiene, Inga ^a   Kazlauskas, Egidijus ^a   Matuliene, Jurgita ^a   Michailoviene, Vilma ^a   Torresan, Jolanta ^a   Jachno, Jelena ^a   Matulis, Daumantas ^a  

^a VILNIUS UNIVERSITY   (Lithuania)

Author keywords

Hsp90; Isothermal titration calorimetry; Pyrazole; Thiadiazole

Indexed keywords

BENZENE DERIVATIVE; HEAT SHOCK PROTEIN 90; HYDROXYL GROUP; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; TANESPIMYCIN; THIADIAZOLE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; DISSOCIATION CONSTANT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOTHERMAL TITRATION CALORIMETRY;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; MOLECULAR STRUCTURE; PYRAZOLES; THIADIAZOLES;

EID: 59749087674     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.01.003     Document Type: Article

References (45)

1. Wandinger S.K., Richter K., and Buchner J. J. Biol. Chem. 283 (2008) 18473
2. Maloney A., and Workman P. Expert Opin. Biol. Ther. 2 (2002) 3
3. Isaacs J.S., Xu W., and Neckers L. Cancer Cell 3 (2003) 213
4. Richter K., and Buchner J. J. Cell. Physiol. 188 (2001) 281
5. Goetz M.P., Toft D.O., Ames M.M., and Erlichman C. Ann. Oncol. 14 (2003) 1169
6. Wegele H., Muller L., and Buchner J. Rev. Physiol. Biochem. Pharmacol. 151 (2004) 1
7. Bagatell R., and Whitesell L. Mol. Cancer Ther. 3 (2004) 1021
8. Roe S.M., Prodromou C., O_Brien R., Ladbury J.E., Piper P.W., and Pearl L.H. J. Med. Chem. 42 (1999) 260
9. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., and Workman P. J. Natl. Cancer Inst. 91 (1999) 1940
10. Solit D.B., Zheng F.F., Drobnjak M., Münster P.N., Higgins B., Verbel D., Heller G., Tong W., Cordon-Cardo C., Agus D.B., Scher H.I., and Rosen N. Clin. Cancer Res. 8 (2002) 986
11. Burger A.M., Fiebig H.-H., Stinson S.F., and Sausville E.A. Anticancer Drugs 15 (2004) 377
12. Banerji U., Clarke P., Walton M., O_Donnell A., Raynaud F., Turner A., Judson I., and Workman P. Proc. Am. Assoc. Cancer Res. 44 (2003) 587
13. Sausville E.A., Tomaszewski J.E., and Ivy P. Curr. Cancer Drug Targets 3 (2003) 377
14. Banerji U., Judson I., and Workman P. Curr. Cancer Drug Targets 3 (2003) 385
15. Goetz M.P., Toft D., Reid J., Ames M., Stensgard B., Safgren S., Adjei A.A., Sloan J., Atherton P., Vasile V., Salazaar S., Adjei A., Croghan G., and Erlichman C. J. Clin. Oncol. 23 (2005) 1078
16. Grem J.L., Morrison G., Guo X.-D., Agnew E., Takimoto C.H., Thomas R., Szabo E., Grochow L., Grollman F., Hamilton J.M., Neckers L., and Wilson R.H. J. Clin. Oncol. 23 (2005) 1885
17. Dymock B.W., Drysdale M.J., McDonald E., and Workman P. Expert Opin. Ther. Patents 14 (2004) 837 20
18. Chiosis G., Vilenchik M., Kim J., and Solit D. Drug Discov. Today 9 (2004) 881
19. Schulte T.W., Akinaga S., Soga S., Sullivan W., Stensgard B., Toft D., and Neckers L.M. Cell Stress Chaperones 3 (1998) 100
20. Soga S., Neckers L.M., Schulte T.W., Shiotsu Y., Akasaka K., Narumi H., Agatsuma T., Ikuina Y., Murakata C., Tamaoki T., and Akinaga S. Cancer Res. 59 (1999) 2931
21. Soga S., Shiotsu Y., Akinaga S., and Sharma S.V. Curr. Cancer Drug Targets 3 (2003) 359
22. Barluenga S., Wang C., Fontaine J.G., Aouadi K., Beebe K., Tsutsumi S., Neckers L., and Winssinger N. Angew. Chem. Int. Ed. 47 (2008) 4432
23. Chiosis G., Merna N.T., Lucas B., Munster P.N., Zheng F.F., Sepp-Lorenzino L., and Rosen N. Chem. Biol. 8 (2001) 289
24. Chiosis G., Lucas B., Shtil A., Huezo H., and Rosen N. Bioorg. Med. Chem. 10 (2002) 3555
25. Llauger L., He H., Kim J., Aguirre J., Rosen N., Peters U., Davies P., and Chiosis G. J. Med. Chem. 48 (2005) 2892
26. Wright L., Barril X., Dymock B., Sheridan L., Surgenor A., Beswick M., Drysdale M., Collier A., Massey A., Davies N., Fink A., Fromont C., Aherne W., Boxall K., Sharp S., Workman P., and Hubbard R.E. Chem. Biol. 11 (2004) 775
27. Dymock B., Barril X., Beswick M., Collier A., Davies N., Drysdale M., Fink A., Fromont C., Hubbard R.E., Massey A., Surgenor A., and Wright L. Bioorg. Med. Chem. Lett. 14 (2004) 325
28. Marcu M.G., Chadli A., Bouhouche I., Catelli M., and Neckers L.M. J. Biol. Chem. 275 (2000) 37181
29. Itoh H., Ogura M., Komatsudo A., Wakui H., Miura A.B., and Tashima Y. Biochem. J. 343 (1999) 697
30. Marcu M.G., and Neckers L.M. Curr. Cancer Drug Targets 3 (2003) 343
31. Cheung K.M.J., Matthews T.P., James K., Rowlands M.G., Boxall K.J., Sharp S.Y., Maloney A., Roe S.M., Prodromou C., Pearl L.H., Aherne G.W., McDonald E., and Workman P. Bioorg. Med. Chem. Lett. 15 (2005) 3338
32. Dymock B.W., Barril X., Brough P.A., Cansfield J.E., Massey A., McDonald E., Hubbard R.E., Surgenor A., Roughley S.D., Webb P., Workman P., Wright L., and Drysdale M.J. J. Med. Chem. 48 (2005) 4212
33. Brough P.A., Aherne W., Barril X., Borgognoni J., Boxall K., Cansfield J.E., Cheung K.-M., Collins I., Davies N.G.M., Drysdale M.J., Dymock B., Eccles S.A., Finch H., Fink A., Hayes A., Howes R., Hubbard R.E., James K., Jordan A.M., Lockie A., Martins V., Massey A., Matthews T., McDonald E., Northfield C.J., Pearl L.H., Prodromou C., Ray S., Raynaud F.I., Roughley S.D., Sharp S.Y., Surgenor A.D., Walmsley L., Webb P., Wood M., Workman P., and Wright L. J. Med. Chem. 51 (2008) 196
34. Gopalsamy A., Shi M., Golas J., Vogan E., Jacob J., Johnson M., Lee F., Nilakantan R., Petersen R., Svenson K., Chopra R., Tam M.S., Wen Y., Ellingboe J., Arndt K., and Boschelli F. J. Med. Chem. 51 (2008) 373
35. Sharp S.Y., Boxall K., Rowlands M., Prodromou C., Roe S.M., Maloney A., Powers M., Clarke P.A., Box G., Sanderson S., Patterson L., Matthews T.P., Cheung K.M.J., Ball K., Hayes A., Raynaud F., Marais R., Pearl L., Eccles S., Aherne W., McDonald E., and Workman P. Cancer Res. 67 (2007) 2206
36. Solit D.B., and Chiosis G. Drug Discov. Today 38 (2008)
37. Messaoudi S., Peyrat J.F., Brion J.D., and Alami M. Anticanc. Agents Med. Chem. 8 (2008) 761
38. 3) Calcd C 59.91%, H 5,34%, N 8.73%. Found: C 60.01%, H 5,45%, N 8.91%.
39. Hurd C.D., and Mori I.R. J. Am. Chem. Soc. 77 (1955) 5359
40. 3S) Calcd C 55.09%, H 3,76%, N 8.03%. Found: C 55.19%, H 3,82%, N 8.14%.
41. Compounds 2a,c-e, 3a,c-e, 4 and 5 were also fully characterised by spectroscopic and elemental analysis data.
42. 4, and 1 μΜ DΤΤ, flash-frozen in liquid nitrogen and stored at -80 °C.
43. Chaires J.B. Annu. Rev. Biophys. 37 (2008) 135
44. 470 to determine the relative amount of soluble XTT formazan in each well. All experiments were performed at least in duplicates.
45. Scudiero D.A., Shoemaker R.H., Paull K.D., Monks A., Tierney S., Nofziger T.H., Currens M.J., Seniff D., and Boyd M.R. Cancer Res. 48 (1988) 4827